Agile Therapeutics (AGRX) Short Interest Ratio & Short Volume → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free AGRX Stock Alerts $0.38 -0.02 (-4.95%) (As of 05/3/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Agile Therapeutics Short Interest DataCurrent Short Volume361,300 sharesPrevious Short Volume222,100 sharesChange Vs. Previous Month+62.67%Dollar Volume Sold Short$196,185.90Short Interest Ratio / Days to Cover0.5Last Record DateMarch 15, 2024Outstanding Shares6,860,000 sharesFloat Size2,850,000 sharesShort Percent of Float12.68%Today's Trading Volume38,847 sharesAverage Trading Volume88,600 sharesToday's Volume Vs. Average44% Short Selling Agile Therapeutics ? Sign up to receive the latest short interest report for Agile Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAGRX Short Interest Over TimeAGRX Days to Cover Over TimeAGRX Percentage of Float Shorted Over Time Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. Agile Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2024361,300 shares $196,185.90 +62.7%12.7%0.5 $0.54 2/29/2024222,100 shares $176,569.50 +4.2%7.9%0.6 $0.80 2/15/2024213,100 shares $260,493.44 +12.2%7.5%0.6 $1.22 1/31/2024189,900 shares $290,547.00 +129.9%6.7%2.8 $1.53 1/15/202482,600 shares $154,462.00 +287.8%3.4%1.3 $1.87 12/31/202321,300 shares $41,535.00 +156.6%0.9%0.4 $1.95 Get the Latest News and Ratings for AGRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/20238,300 shares $16,766.00 +23.9%0.4%0.2 $2.02 11/30/20236,700 shares $13,869.00 -62.8%0.3%0.2 $2.07 11/15/202318,000 shares $40,140.00 +12.5%0.8%0.4 $2.23 10/31/202316,000 shares $28,960.00 +263.6%0.9%0.4 $1.81 10/15/20234,400 shares $7,832.00 -76.5%0.2%0.1 $1.78 9/30/202318,700 shares $44,880.00 +567.9%1.0%0.4 $2.40 9/15/20232,800 shares $5,852.00 -73.8%0.2%0.1 $2.09 8/31/202310,700 shares $27,820.00 -48.3%0.6%0.1 $2.60 8/15/202320,700 shares $45,126.00 -46.2%1.1%0.2 $2.18 7/31/202338,500 shares $111,650.00 -45.8%1.4%0.3 $2.90 7/15/202371,000 shares $202,350.00 -42.5%2.5%0.6 $2.85 6/30/2023123,400 shares $364,030.00 -36.7%4.4%1.1 $2.95 6/15/2023194,800 shares $633,100.00 +146.3%6.7%1.9 $3.25 5/31/202379,100 shares $299,789.00 +16.5%2.7%2.8 $3.79 5/15/202367,900 shares $322,525.00 +46.0%6.9%2.6 $4.75 4/30/202346,500 shares $299,925.00 +37.6%5.3%2.4 $6.45 4/15/202333,800 shares $235,924.00 +350.7%3.8%1.8 $6.98 3/31/20237,500 shares $1,680.00 -96.7%0.9%0.4 $0.22 3/15/2023225,700 shares $48,818.91 -39.7%0.6%0.3 $0.22 2/28/2023374,400 shares $89,818.56 -28.7%1.0%0.5 $0.24 2/15/2023524,900 shares $152,221.00 -25.0%1.3%0.7 $0.29 1/31/2023699,500 shares $188,865.00 +2.5%1.8%0.8 $0.27 1/15/2023682,600 shares $197,954.00 -0.1%1.7%0.8 $0.29 12/30/2022683,200 shares $155,086.40 -0.1%1.7%0.8 $0.23 12/15/2022684,100 shares $132,715.40 -18.7%1.7%0.8 $0.19 11/30/2022841,200 shares $176,652.00 -22.8%2.1%0.8 $0.21 11/15/20221,090,000 shares $253,207.00 -31.0%2.8%0.9 $0.23 10/31/20221,580,000 shares $440,820.00 +29.5%4.2%0.8 $0.28 10/15/20221,220,000 shares $318,786.00 -2.4%3.2%0.5 $0.26 9/30/20221,250,000 shares $371,125.00 -15.0%3.3%0.3 $0.30 9/15/20221,470,000 shares $588,000.00 -6.4%3.9%0.1 $0.40 8/31/20221,570,000 shares $631,925.00 -19.5%4.1%0.1 $0.40 8/15/20221,950,000 shares $1.05 million +42.3%5.1%0.2 $0.54 7/31/20221,370,000 shares $699,933.00 +77.4%3.6%0.1 $0.51Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. AGRX Short Interest - Frequently Asked Questions What is Agile Therapeutics' current short interest? Short interest is the volume of Agile Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 361,300 shares of AGRX short. 12.68% of Agile Therapeutics' shares are currently sold short. Learn More on Agile Therapeutics' current short interest. Which institutional investors are shorting Agile Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Agile Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Agile Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.68% of Agile Therapeutics' floating shares are currently sold short. Is Agile Therapeutics' short interest increasing or decreasing? Agile Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 361,300 shares, an increase of 62.7% from the previous total of 222,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Agile Therapeutics' float size? Agile Therapeutics currently has issued a total of 6,860,000 shares. Some of Agile Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Agile Therapeutics currently has a public float of 2,850,000 shares. How does Agile Therapeutics' short interest compare to its competitors? 12.68% of Agile Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Agile Therapeutics: Avenue Therapeutics, Inc. (32.81%), Aravive, Inc. (1.81%), Virpax Pharmaceuticals, Inc. (1.70%), Phio Pharmaceuticals Corp. (0.75%), Biophytis S.A. (2.62%), GeoVax Labs, Inc. (0.28%), Cyclacel Pharmaceuticals, Inc. (3.20%), Clever Leaves Holdings Inc. (0.61%), Revelation Biosciences, Inc. (1.13%), 60 Degrees Pharmaceuticals, Inc. (1.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Agile Therapeutics stock? Short selling AGRX is an investing strategy that aims to generate trading profit from Agile Therapeutics as its price is falling. AGRX shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Agile Therapeutics? A short squeeze for Agile Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AGRX, which in turn drives the price of the stock up even further. How often is Agile Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AGRX, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Avenue Therapeutics Short Interest Data Aravive Short Interest Data Virpax Pharmaceuticals Short Interest Data Phio Pharmaceuticals Short Interest Data Biophytis Short Interest Data GeoVax Labs Short Interest Data Cyclacel Pharmaceuticals Short Interest Data Clever Leaves Short Interest Data Revelation Biosciences Short Interest Data 60 Degrees Pharmaceuticals Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AGRX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith